Hesham K. Abdelaziz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hesham K. Abdelaziz has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Ranjit More
Blackpool Teaching Hospitals, NHS Foundation Trust, Blackpool, United Kingdom
4 shared publications - Alok Shah
Department of Cardiology, Sir HN Reliance Foundation Hospital and Research Centre, Mumbai 400004, Maharashtra, India
3 shared publications Andrew Wiper
Blackpool Teaching Hospitals, NHS Foundation Trust, Blackpool, United Kingdom
3 shared publicationsDavid H. Roberts
Lancashire Cardiac Center, Blackpool Victoria Hospital, Blackpool, UK
3 shared publications- Maciej Dębski
Norwich Medical School, University of East Anglia, Norwich, United Kingdom
3 shared publications - Amr Gamal
Lancashire Cardiac Centre, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, Lancashire FY3 8NR, UK
2 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Clinical Outcomes of the Allegra Transcatheter System in Bioprosthetic Aortic Valve Failure: A Multicentre Valve‐in‐Valve Registry
Introduction: The prevalence of bioprosthetic aortic valve failure is increasing due to the broader use of bioprosthetic valves, both surgical and transcatheter, and an ageing population. Registry data indicate a higher risk of coronary obstruction and elevated gradients following valve‐in‐valve transcatheter aortic valve implantation (TAVI). We report outcomes of the Allegra transcatheter heart valve system in valve‐in‐valve TAVI. Methods: In this retrospective multicentre cohort study, all patients undergoing valve‐in‐valve TAVI with the Allegra system between 2019 and 2025 at five UK centers were included. The combined primary outcomes were technical success, device success, and early safety at 30 days, as per the VARC‐3 (Valve Academic Research Consortium‐3) criteria. A key secondary outcome was all‐cause mortality at the longest documented follow‐up. Results: A total of 106 patients underwent valve‐in‐valve TAVI. The mean age was 79 ± 6 years, with 57.5% being female. Almost half of the patients had an index valve ≤ 21 mm, with an STS (Society of Thoracic Surgery) score of 7.1% (5.1–12.0). The post‐implant aortic valve mean pressure gradient was 12 ± 6 mmHg, and the mean valve area was 1.7 ± 0.5 cm 2 . The combined primary outcomes were technical success of 86.8% (CI 80.3%–93.2%), device success of 75.5% (CI 67.3%–83.7%), and early safety of 86.8% (CI 80.3%–93.2%). All‐cause mortality at 30 days was 0%. All‐cause mortality occurred in 6.6% at a median follow‐up of 15 months. Conclusions: The Allegra TAVI system demonstrates promising technical and device success rates, with early safety and good post‐implant haemodynamic performance in high‐risk patients undergoing valve‐in‐valve TAVI. Larger randomized trials are needed to confirm these results.
- 21 August 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
Open AccessClinical Outcomes of the Allegra Transcatheter System in Bioprosthetic Aortic Valve Failure: A Multicentre Valve‐in‐Valve Registry
Introduction: The prevalence of bioprosthetic aortic valve failure is increasing due to the broader use of bioprosthetic valves, both surgical and transcatheter, and an ageing population. Registry data indicate a higher risk of coronary obstruction and elevated gradients following valve‐in‐valve transcatheter aortic valve implantation (TAVI). We report outcomes of the Allegra transcatheter heart valve system in valve‐in‐valve TAVI. Methods: In this retrospective multicentre cohort study, all patients undergoing valve‐in‐valve TAVI with the Allegra system between 2019 and 2025 at five UK centers were included. The combined primary outcomes were technical success, device success, and early safety at 30 days, as per the VARC‐3 (Valve Academic Research Consortium‐3) criteria. A key secondary outcome was all‐cause mortality at the longest documented follow‐up. Results: A total of 106 patients underwent valve‐in‐valve TAVI. The mean age was 79 ± 6 years, with 57.5% being female. Almost half of the patients had an index valve ≤ 21 mm, with an STS (Society of Thoracic Surgery) score of 7.1% (5.1–12.0). The post‐implant aortic valve mean pressure gradient was 12 ± 6 mmHg, and the mean valve area was 1.7 ± 0.5 cm 2 . The combined primary outcomes were technical success of 86.8% (CI 80.3%–93.2%), device success of 75.5% (CI 67.3%–83.7%), and early safety of 86.8% (CI 80.3%–93.2%). All‐cause mortality at 30 days was 0%. All‐cause mortality occurred in 6.6% at a median follow‐up of 15 months. Conclusions: The Allegra TAVI system demonstrates promising technical and device success rates, with early safety and good post‐implant haemodynamic performance in high‐risk patients undergoing valve‐in‐valve TAVI. Larger randomized trials are needed to confirm these results.
- Open Access
- 4 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5242
Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR): How It Started, How It’s Going, and Where It’s Going
Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has come a long way since the first-in-human implant by Prof Cribier & colleagues in 2002. Initially a consideration for inoperable/high-surgical-risk patients, TAVI is now indicated in patients with severe tricuspid aortic stenosis and suitable anatomy aged 70 or higher. This has been made possible due to improvements in preprocedural planning, performance upgrades to and evolution of transcatheter heart valve (THV) systems and increasing operator experience. Younger age at index implantation, complexities of redo TAVI planning and methods to improve THV durability are the next frontiers. This review summarizes these advancements while emphasizing preprocedural planning, current guidelines, and individualized device selection, with a brief note on polymeric heart valves—developed to overcome the disadvantageous bioprosthetic dysfunction seen with current THVs.
- 4 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5242
Open AccessTranscatheter Aortic Valve Implantation/Replacement (TAVI/TAVR): How It Started, How It’s Going, and Where It’s Going
Transcatheter Aortic Valve Implantation/Replacement (TAVI/TAVR) has come a long way since the first-in-human implant by Prof Cribier & colleagues in 2002. Initially a consideration for inoperable/high-surgical-risk patients, TAVI is now indicated in patients with severe tricuspid aortic stenosis and suitable anatomy aged 70 or higher. This has been made possible due to improvements in preprocedural planning, performance upgrades to and evolution of transcatheter heart valve (THV) systems and increasing operator experience. Younger age at index implantation, complexities of redo TAVI planning and methods to improve THV durability are the next frontiers. This review summarizes these advancements while emphasizing preprocedural planning, current guidelines, and individualized device selection, with a brief note on polymeric heart valves—developed to overcome the disadvantageous bioprosthetic dysfunction seen with current THVs.
- Open Access
- 6 May 2026
- Published by MDPI AG in Preprints.org
Transcatheter Aortic Valve Implantation/ Replacement (Tavi/ Tavr): How It Started, How Its Going, Where Its Going
Transcatheter Aortic Valve Implantation/ Replacement (TAVI/TAVR) has come a long was since the first in human implant done by Prof Cribier & colleagues in 2002. Initially a consideration in inoperable/ high surgical risk patients, TAVI is now indicated in patients with severe tricuspid aortic stenosis and suitable anatomy aged 70 or higher. This has been possible due to improvements in pre procedural planning, performance upgrades & evolution of transcatheter heart valve (THV) systems and increasing operator experience. Considering improving longevity and relatively younger ages at index implantation, complexities of redo TAVI planning and methods to improve THV durability are the next frontiers. This review summarizes these advancements while emphasizing on pre procedural planning, current guidelines, individualized device selection with a brief note on polymeric heart valves - developed to overcome the disadvantageous bioprosthetic dysfunction seen with current THVs.
- 6 May 2026
- Published by MDPI AG in Preprints.org
Open AccessTranscatheter Aortic Valve Implantation/ Replacement (Tavi/ Tavr): How It Started, How Its Going, Where Its Going
Transcatheter Aortic Valve Implantation/ Replacement (TAVI/TAVR) has come a long was since the first in human implant done by Prof Cribier & colleagues in 2002. Initially a consideration in inoperable/ high surgical risk patients, TAVI is now indicated in patients with severe tricuspid aortic stenosis and suitable anatomy aged 70 or higher. This has been possible due to improvements in pre procedural planning, performance upgrades & evolution of transcatheter heart valve (THV) systems and increasing operator experience. Considering improving longevity and relatively younger ages at index implantation, complexities of redo TAVI planning and methods to improve THV durability are the next frontiers. This review summarizes these advancements while emphasizing on pre procedural planning, current guidelines, individualized device selection with a brief note on polymeric heart valves - developed to overcome the disadvantageous bioprosthetic dysfunction seen with current THVs.
- 1 February 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 164, 103-110
Quality of Life Assessment in Patients Undergoing Trans-Catheter Aortic Valve Implantation Using MacNew Questionnaire
- 1 February 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 164, 103-110
Quality of Life Assessment in Patients Undergoing Trans-Catheter Aortic Valve Implantation Using MacNew Questionnaire
- Open Access
- 4 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (11) , ytab398
Ultra-low contrast, complex left main coronary intervention case series using novel intravascular ultrasound technology
Contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) carries a high morbidity and mortality. Ultra-low contrast percutaneous coronary intervention (ULPCI) has previously been described. Complex left main (LM) ULPCI using two-stent strategy guided by novel intravascular ultrasound (IVUS) co-registration software has not been described. We report a series of complex LM ULPCI using IVUS co-registration. Five patients with estimated glomerular filtration rate ≤20 mL/min who presented with stable angina or non-ST segment elevation acute coronary syndrome underwent percutaneous coronary intervention (PCI). The patients previously had diagnostic angiography performed as a separate procedure. Successful LM ULPCI was performed in all patients with a provisional and two-stent bifurcation strategies. These were complex procedures, some of which required haemodynamic support and rotational atherectomy. This report describes the first ULPCI using a dedicated two-stent LM bifurcation strategy and using rotational atherectomy and IVUS co-registration. This technology facilitated complex PCI in this high-risk patient group with minimal contrast use (≤6 mL) with optimal results and no patients developed acute kidney injury after intervention. The adaptation of ULPCI to daily practice in patients at risk of CIN will improve treatment for this underserved patient group.
- 4 November 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 5 (11) , ytab398
Open AccessUltra-low contrast, complex left main coronary intervention case series using novel intravascular ultrasound technology
Contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) carries a high morbidity and mortality. Ultra-low contrast percutaneous coronary intervention (ULPCI) has previously been described. Complex left main (LM) ULPCI using two-stent strategy guided by novel intravascular ultrasound (IVUS) co-registration software has not been described. We report a series of complex LM ULPCI using IVUS co-registration. Five patients with estimated glomerular filtration rate ≤20 mL/min who presented with stable angina or non-ST segment elevation acute coronary syndrome underwent percutaneous coronary intervention (PCI). The patients previously had diagnostic angiography performed as a separate procedure. Successful LM ULPCI was performed in all patients with a provisional and two-stent bifurcation strategies. These were complex procedures, some of which required haemodynamic support and rotational atherectomy. This report describes the first ULPCI using a dedicated two-stent LM bifurcation strategy and using rotational atherectomy and IVUS co-registration. This technology facilitated complex PCI in this high-risk patient group with minimal contrast use (≤6 mL) with optimal results and no patients developed acute kidney injury after intervention. The adaptation of ULPCI to daily practice in patients at risk of CIN will improve treatment for this underserved patient group.
- Open Access
- 27 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0241357
Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors
Non-alcoholic fatty liver disease (NAFLD) is common and strongly associated with the metabolic syndrome. Though NAFLD may progress to end-stage liver disease, the top cause of mortality in NAFLD is cardiovascular disease (CVD). Most of the data on liver-related mortality in NAFLD derives from specialist liver centres. It is not clear if the higher reported mortality rates in individuals with non-cirrhotic NAFLD are entirely accounted for by complications of atherosclerosis and diabetes. Therefore, we aimed to describe the CVD burden and mortality in NAFLD when adjusting for metabolic risk factors using a ‘real world’ cohort. We performed a retrospective study of patients followed-up after an admission to non-specialist hospitals with a NAFLD-spectrum diagnosis. Non-cirrhotic NAFLD and NAFLD-cirrhosis patients were defined by ICD-10 codes. Cases were age-/sex-matched with non-NAFLD hospitalised patients. All-cause mortality over 14-years follow-up after discharge was compared between groups using Cox proportional hazard models adjusted for demographics, CVD, and metabolic syndrome components. We identified 1,802 patients with NAFLD-diagnoses: 1,091 with non-cirrhotic NAFLD and 711 with NAFLD-cirrhosis, matched to 24,737 controls. There was an increasing burden of CVD with progression of NAFLD: for congestive heart failure 3.5% control, 4.2% non-cirrhotic NAFLD, 6.6% NAFLD-cirrhosis; and for atrial fibrillation 4.7% control, 5.9% non-cirrhotic NAFLD, 12.1% NAFLD-cirrhosis. Over 14-years follow-up, crude mortality rates were 14.7% control, 13.7% non-cirrhotic NAFLD, and 40.5% NAFLD-cirrhosis. However, after adjusting for demographics, non-cirrhotic NAFLD (HR 1.3 (95% CI 1.1–1.5)) as well as NAFLD-cirrhosis (HR 3.7 (95% CI 3.0–4.5)) patients had higher mortality compared to controls. These differences remained after adjusting for CVD and metabolic syndrome components: non-cirrhotic NAFLD (HR 1.2 (95% CI 1.0–1.4)) and NAFLD-cirrhosis (HR 3.4 (95% CI 2.8–4.2)). In conclusion, from a large non-specialist registry of hospitalised patients, those with non-cirrhotic NAFLD had increased overall mortality compared to controls even after adjusting for CVD.
- 27 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0241357
Open AccessHospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors
Non-alcoholic fatty liver disease (NAFLD) is common and strongly associated with the metabolic syndrome. Though NAFLD may progress to end-stage liver disease, the top cause of mortality in NAFLD is cardiovascular disease (CVD). Most of the data on liver-related mortality in NAFLD derives from specialist liver centres. It is not clear if the higher reported mortality rates in individuals with non-cirrhotic NAFLD are entirely accounted for by complications of atherosclerosis and diabetes. Therefore, we aimed to describe the CVD burden and mortality in NAFLD when adjusting for metabolic risk factors using a ‘real world’ cohort. We performed a retrospective study of patients followed-up after an admission to non-specialist hospitals with a NAFLD-spectrum diagnosis. Non-cirrhotic NAFLD and NAFLD-cirrhosis patients were defined by ICD-10 codes. Cases were age-/sex-matched with non-NAFLD hospitalised patients. All-cause mortality over 14-years follow-up after discharge was compared between groups using Cox proportional hazard models adjusted for demographics, CVD, and metabolic syndrome components. We identified 1,802 patients with NAFLD-diagnoses: 1,091 with non-cirrhotic NAFLD and 711 with NAFLD-cirrhosis, matched to 24,737 controls. There was an increasing burden of CVD with progression of NAFLD: for congestive heart failure 3.5% control, 4.2% non-cirrhotic NAFLD, 6.6% NAFLD-cirrhosis; and for atrial fibrillation 4.7% control, 5.9% non-cirrhotic NAFLD, 12.1% NAFLD-cirrhosis. Over 14-years follow-up, crude mortality rates were 14.7% control, 13.7% non-cirrhotic NAFLD, and 40.5% NAFLD-cirrhosis. However, after adjusting for demographics, non-cirrhotic NAFLD (HR 1.3 (95% CI 1.1–1.5)) as well as NAFLD-cirrhosis (HR 3.7 (95% CI 3.0–4.5)) patients had higher mortality compared to controls. These differences remained after adjusting for CVD and metabolic syndrome components: non-cirrhotic NAFLD (HR 1.2 (95% CI 1.0–1.4)) and NAFLD-cirrhosis (HR 3.4 (95% CI 2.8–4.2)). In conclusion, from a large non-specialist registry of hospitalised patients, those with non-cirrhotic NAFLD had increased overall mortality compared to controls even after adjusting for CVD.
- 1 April 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (8) , 1239-1248
Meta-Analysis Comparing Percutaneous to Surgical Access in Trans-Femoral Transcatheter Aortic Valve Implantation
- 1 April 2020
- Published by Elsevier in The American Journal of Cardiology
- Vol. 125 (8) , 1239-1248
Meta-Analysis Comparing Percutaneous to Surgical Access in Trans-Femoral Transcatheter Aortic Valve Implantation
- 25 March 2020
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 19 (2) , 55-57
COVID-19 Pandemic and Acute Myocardial Infarction: Management Protocol From a British Cardiac Centre
An abstract is unavailable. This article is available as a PDF only.
- 25 March 2020
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 19 (2) , 55-57
COVID-19 Pandemic and Acute Myocardial Infarction: Management Protocol From a British Cardiac Centre
An abstract is unavailable. This article is available as a PDF only.
- 1 January 2020
- Published by Elsevier
Contributors